Ertugliflozin and Sitagliptin Co-administration Factorial Study (VERTIS FACTORAL, MK-8835-005)
Status:
Completed
Trial end date:
2016-05-26
Target enrollment:
Participant gender:
Summary
This is a study of co-administration of ertugliflozin (MK-8835/PF-04971729) and sitagliptin
given together or alone along with metformin in participants with Type 2 diabetes mellitus
(T2DM) and inadequate glycemic control on metformin monotherapy. The primary hypothesis of
this study is that ertugliflozin 15 mg daily plus sitagliptin 100 mg daily provides greater
hemoglobin A1C (A1C)-lowering compared with sitagliptin 100 mg daily alone.